Amanta Healthcare IPO GMP today
Amanta Healthcare shares are commanding a 12% premium in the grey market over the upper end of the IPO price band, set at Rs 126 per share, a sign of positive investor sentiment ahead of the listing.
Note: The Grey Market Premium (GMP) represents the unofficial premium at which IPO shares trade before their official listing. While it reflects market expectations and potential listing gains, it is not a regulated or guaranteed indicator.
Amanta Healthcare IPO subscription status:
On the second day of bidding, Amanta Healthcare’s IPO received an enthusiastic response, with overall subscriptions reaching 6.28 times the total shares on offer.
Retail Individual Investors (RIIs) were the most active, applying for 8.86 times the 35 lakh shares allocated to them—demonstrating strong demand from small and individual investors.
Non-Institutional Investors (NIIs), which typically include high-net-worth individuals and corporates, subscribed 8.59 times their quota of 15 lakh shares.
In contrast, demand from Qualified Institutional Buyers (QIBs)—such as mutual funds, insurance companies, and foreign institutional investors—was relatively muted, with only 4% of the 20 lakh shares reserved for them subscribed on Day 1. However, QIB participation often increases closer to the subscription deadline, so stronger interest may still emerge.
Amanta Healthcare IPO details:
The IPO will remain open for three days, closing on Wednesday, September 3. Ahmedabad-based Amanta Healthcare is a pharmaceutical company specialising in the production of sterile liquid formulations and medical devices. The company has set a price band of Rs 120–126 per share for the offering.
The IPO consists entirely of a fresh issue of 1 crore equity shares. The shares are expected to be listed on both the BSE and NSE on September 8.
About the company
Amanta Healthcare focuses on the development and marketing of sterile injectables, IV fluids, ophthalmic solutions, respiratory care products, irrigation solutions, and medical devices. Its core technology platforms include SteriPort (ISBM) and ABFS (Aseptic Blow-Fill-Seal).
The company has built a strong domestic presence with a network of over 320 distributors and stockists, while also exporting to regions such as Africa, Latin America, the UK, and other emerging markets. In FY25, domestic branded generics accounted for around 55% of its revenue, followed by 33% from international sales and 10% from product partnerships and contract manufacturing.
Amanta’s manufacturing facility in Hariyala, Gujarat, is equipped with seven production lines for both Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), and is certified by regulatory authorities in India and several international markets.
Financials
Amanta Healthcare posted a consolidated revenue of Rs 274.7 crore in FY25, a marginal decline from Rs 280.3 crore in FY24. Despite the dip in revenue, the company recorded a strong improvement in profitability, with profit after tax rising sharply to Rs 10.5 crore in FY25, up from Rs 3.6 crore in the previous fiscal year.
IPO Objectives
The company plans to utilise Rs 70 crore from the IPO proceeds to expand its SteriPort manufacturing line, Rs 30.1 crore to set up a new production line for Small Volume Parenterals (SVPs), and the remaining funds will be allocated for general corporate purposes.
Should You Subscribe?
Investor4Edu has recommended subscribing to the IPO, highlighting Amanta Healthcare’s strong potential to benefit from the rising demand for sterile liquid pharmaceuticals and medical devices in both domestic and international markets.
At the upper end of the price band, the stock is valued at around 47 times its post-issue FY25 earnings, suggesting the IPO is reasonably priced.
With certifications in over 120 jurisdictions, a broad product portfolio, and a strategic focus on sterile pharmaceuticals, Amanta Healthcare appears well-positioned for sustained growth. Investor sentiment in the next two days, along with grey market trends, will provide further clarity ahead of the stock’s listing.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
as a Reliable and Trusted News Source